研究

治疗

HR+/HER2 + DFS

HR-/HER2 + DFS

参考文献

HERA

1. 1 year of trastuzumab 2.2 year of trastuzumab

1.1.73%

2.2. 71%

1.1. 68%

2.2. 68%

[22]

ALTTO

trastuzumab and/or lapatinib

83.87%

82.17%

ExteNET

neratinib

92.80%

90.56%

[34]